文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

一名接受免疫抑制治疗的患者出现内脏和黏膜皮肤利什曼病复发。

Recurrence of visceral and muco-cutaneous leishmaniasis in a patient under immunosuppressive therapy.

作者信息

Darcis Gilles, Van der Auwera Gert, Giot Jean-Baptiste, Hayette Marie-Pierre, Tassin Françoise, Arrese Estrada Jorge, Cnops Lieselotte, Moutschen Michel, de Leval Laurence, Leonard Philippe

机构信息

Centre Hospitalier Universitaire (CHU) de Liège, Liège, Belgium.

Institute of Tropical Medicine, Antwerp, Belgium.

出版信息

BMC Infect Dis. 2017 Jul 7;17(1):478. doi: 10.1186/s12879-017-2571-x.


DOI:10.1186/s12879-017-2571-x
PMID:28687071
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5501116/
Abstract

BACKGROUND: Leishmaniasis is a protozoan disease caused by parasites of the genus Leishmania, transmitted to humans by sandflies. The diagnosis of leishmaniasis is often challenging as it mimics many other infectious or malignant diseases. The disease can present in three ways: cutaneous, mucocutaneous, or visceral leishmaniasis, which rarely occur together or consecutively. CASE PRESENTATION: The patient was a 52 years old immunosuppressed Belgian woman with a long history of severe rheumatoid arthritis. She underwent bone marrow biopsy to explore thrombocytopenia. Diagnosis of visceral leishmaniasis was made by identification of Leishman Donovan (LD) bodies in macrophages. Treatment with liposomal amphotericin B was successful. She later developed cutaneous leishmaniasis treated with amphotericin B lipid complex. She next presented with relapsing cutaneous lesions followed by rapidly progressing lymphadenopathies. Biopsy confirmed the diagnosis of leishmaniasis. Treatments by miltefosine, amphotericin B, N-methyl-glucamine antimoniate were subsequently initiated. She later presented a recurrent bone marrow involvement treated with intramuscular paromomycin and miltefosine. She died two years later from leukemia. At the time of death, she presented with a mucosal destruction of the nose. A Leishmania-specific PCR (Polymerase Chain Reaction) identified L. infantum as etiological agent. CONCLUSIONS: Clinicians should be aware of the potential concomitant or sequential involvement of multiple anatomic localizations of Leishmania in immunosuppressed patients.

摘要

背景:利什曼病是一种由利什曼原虫属寄生虫引起的原生动物疾病,通过白蛉传播给人类。利什曼病的诊断通常具有挑战性,因为它与许多其他感染性或恶性疾病相似。该疾病可表现为三种形式:皮肤利什曼病、黏膜皮肤利什曼病或内脏利什曼病,很少同时或相继发生。 病例介绍:患者为一名52岁免疫抑制的比利时女性,有严重类风湿关节炎病史。她接受了骨髓活检以探究血小板减少症。通过在巨噬细胞中鉴定杜氏利什曼原虫(LD)小体确诊为内脏利什曼病。脂质体两性霉素B治疗成功。她后来患上皮肤利什曼病,接受了两性霉素B脂质复合物治疗。接下来她出现复发性皮肤病变,随后淋巴结病迅速进展。活检确诊为利什曼病。随后开始用米替福新、两性霉素B、葡甲胺锑酸盐进行治疗。她后来出现复发性骨髓受累,接受了肌肉注射巴龙霉素和米替福新治疗。两年后她死于白血病。死亡时,她出现了鼻部黏膜破坏。利什曼原虫特异性聚合酶链反应(PCR)鉴定为婴儿利什曼原虫为病原体。 结论:临床医生应意识到在免疫抑制患者中利什曼原虫可能同时或相继累及多个解剖部位。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f18/5501116/7f5b676008eb/12879_2017_2571_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f18/5501116/9ebf2ed98a1f/12879_2017_2571_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f18/5501116/7f5b676008eb/12879_2017_2571_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f18/5501116/9ebf2ed98a1f/12879_2017_2571_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f18/5501116/7f5b676008eb/12879_2017_2571_Fig2_HTML.jpg

相似文献

[1]
Recurrence of visceral and muco-cutaneous leishmaniasis in a patient under immunosuppressive therapy.

BMC Infect Dis. 2017-7-7

[2]
Leishmaniasis.

Lancet. 1999-10-2

[3]
Post-kala-azar dermal leishmaniasis and leprosy: case report and literature review.

BMC Infect Dis. 2015-11-23

[4]
Short report: Development of post-kala-azar dermal leishmaniasis (PKDL) in miltefosine-treated visceral leishmaniasis.

Am J Trop Med Hyg. 2009-3

[5]
Leishmaniasis in immunosuppressed individuals.

Clin Microbiol Infect. 2014-2-20

[6]
A severe case of visceral leishmaniasis and liposomal amphotericin B treatment failure in an immunosuppressed patient 15 years after exposure.

BMC Infect Dis. 2017-1-17

[7]
Cutaneous leishmaniasis treatment.

Travel Med Infect Dis. 2007-5

[8]
Post-kala-azar dermal leishmaniasis due to Leishmania infantum in an HIV-negative patient treated with miltefosine.

J Travel Med. 2022-11-4

[9]
Successful Treatment of Disseminated Cutaneous Leishmaniasis With Liposomal Amphotericin B and Miltefosine in an Eight-year-old Girl.

Pediatr Infect Dis J. 2018-3

[10]
Assessing the Efficacy and Safety of Liposomal Amphotericin B and Miltefosine in Combination for Treatment of Post Kala-Azar Dermal Leishmaniasis.

J Infect Dis. 2020-2-3

引用本文的文献

[1]
Case Report: Disseminated leishmaniasis and rheumatoid arthritis: navigating a clinical conundrum.

Front Immunol. 2025-6-5

[2]
Systematic Review of Treatment Failure and Clinical Relapses in Leishmaniasis from a Multifactorial Perspective: Clinical Aspects, Factors Associated with the Parasite and Host.

Trop Med Infect Dis. 2023-8-29

[3]
Recurrent mucosal leishmaniasis of the epiglottis in an immunosuppressed patient.

IDCases. 2023-7-25

[4]
Evaluation of the In Vitro Antiparasitic Effect of the Essential Oil of and Its Chemical Composition Analysis.

Molecules. 2022-4-25

[5]
Visceral and mucosal leishmaniasis mimicking Wilson disease and oral neoplasia.

IDCases. 2022-3-5

[6]
Causative Agents of American Tegumentary Leishmaniasis Are Able to Infect 3T3-L1 Adipocytes .

Front Cell Infect Microbiol. 2022

[7]
Unusual clinical presentation of cutaneous leishmaniasis in a patient with corticosteroid-induced immunosuppression.

Clin Case Rep. 2020-11-24

[8]
Visceral Dissemination of Mucocutaneous Leishmaniasis in a Kidney Transplant Recipient.

Pathogens. 2020-12-30

[9]
A comprehensive systematic review of leishmaniasis in patients undergoing drug-induced immunosuppression for the treatment of dermatological, rheumatological and gastroenterological diseases.

Rev Inst Med Trop Sao Paulo. 2020

[10]
Immune Profile of the Nasal Mucosa in Patients with Cutaneous Leishmaniasis.

Infect Immun. 2020-4-20

本文引用的文献

[1]
Reactivation of cutaneous and mucocutaneous tegumentary leishmaniasis in rheumatoid arthritis patients: an emerging problem?

Rev Inst Med Trop Sao Paulo. 2017-4-3

[2]
Localized mucosal leishmaniasis caused by Leishmania infantum mimicking cancer in the rhinolaryngeal region.

Int J Infect Dis. 2016-9

[3]
Antimony to Cure Visceral Leishmaniasis Unresponsive to Liposomal Amphotericin B.

PLoS Negl Trop Dis. 2016-1-6

[4]
Spread of Leishmania infantum in Europe with dog travelling.

Vet Parasitol. 2015-9-30

[5]
Mucosal leishmaniasis mimicking squamous cell carcinoma in a liver transplant recipient.

Transpl Infect Dis. 2015-6

[6]
Visceral leishmaniasis mimicking systemic lupus erythematosus: Case series and a systematic literature review.

Semin Arthritis Rheum. 2015-6

[7]
Mucosal relapse of visceral leishmaniasis in a child treated with anti-TNFα.

Int J Infect Dis. 2015-4

[8]
Mucosal leishmaniasis of the tongue caused by Leishmania infantum in an immunocompetent woman.

Int J Dermatol. 2015-1

[9]
Slowly Progressive Keratouveitis in a Patient with Known Systemic Leishmaniasis and HIV.

Ocul Immunol Inflamm. 2015-6

[10]
Heat-shock protein 70 gene sequencing for Leishmania species typing in European tropical infectious disease clinics.

Euro Surveill. 2013-7-25

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索